GSK Prices Tafinlar At $7,600/month, Undercutting Roche’s Zelboraf
Executive Summary
At a time when $10,000-per-month pricing is the norm in oncology, GSK has priced its just-approved BRAF inhibitor Tafinlar at $7,600, on the lower end by today’s standards. Company says it is planning to file the combination of Tafinlar with Mekinist – also just approved by FDA – in a matter of weeks in the U.S.
You may also be interested in...
GSK’s Mekinist/Tafinlar Combo Pushes The Price Bar
GSK’s MEK inhibitor Mekinist and BRAF inhibitor Tafinlar are the first two targeted therapies approved in combination for the treatment of metastatic melanoma. The prices of the separate components are below other comparable oncology launches, but the combination will push the price to over $17,115 for a month of treatment.
GSK Establishes Oncology Consortium With An Eye On Combinations
The company has aligned with six leading cancer centers to study investigational cancer drugs, with the ambition of advancing novel combinations, including both targeted therapies and immunotherapies.
Vical Shifts To Infectious Disease After Allovectin Fails In Melanoma
CEO Vijay Samant defends Vical’s DNA-based technology platform after 20 years of development culminates in Phase III failure. But the platform still shows promise in other therapeutic areas, Vical says as the company absorbs a major blow to stock price.